Bone marrow-derived mesenchymal stem cell therapy (Guangzhou Institute of Respiratory Disease)

N/A

Report date: 2025/02/02 20:00:08

Base Information

Drug NameBone marrow-derived mesenchymal stem cell therapy (Guangzhou Institute of Respiratory Disease)
Drug Alias NameBM-MSCs
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Primary Ovarian Insufficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJordanMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPending
Originator CompaniesGuangzhou Institute Of Respiratory Health
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Jordan
Inactive CompaniesGuangzhou Institute Of Respiratory Health
Active IndicationsPrimary Ovarian Insufficiency
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A